scholarly journals Understanding and Dealing the SARS-CoV-2 Infection: An Updated Concise Review

2021 ◽  
Vol 24 (1) ◽  
pp. 61-75
Author(s):  
Md Jamal Hossain ◽  
Md Ruhul Kuddus ◽  
Mohammad A Rashid ◽  
Md Zakir Sultan
Keyword(s):  
Viral Infection ◽  
Vaccine Development ◽  
Herd Immunity ◽  
Critical Time ◽  
Pharmaceutical Journal ◽  
Viral Agent ◽  
The World ◽  
Current Century ◽  
Pass Through ◽  
Novel Coronavirus

Viral infection has made the world to pass through the most critical time of the current century. In December 2019, the Wuhan city of China faced a novel etiological viral agent with atypical secondary pneumonia. The unique virus was severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that caused coronavirus disease 2019 (COVID-19) pandemic. According to the worldometer data, as of December 24, 2020, the world lost more than 1.74 million lives and infected more than 79.3 million people with the novel coronavirus-2. As there is no approved drug to combat the disease or vaccine against the virus, the infection continuously triumphed over the current medical system. The epidemiological analysis showed that geriatric patients are generally the most susceptible to the viral infection, and pediatric patients exhibited milder complications. The clinical characteristics of COVID-19 displayed that the most frequent symptoms are dry cough, fever, dyspnea, and sputum production. Herd immunity is a tested strategy that could moderate viral transmission in developing countries. In this study, authors abridged the epidemiological outcomes, clinical features, and pathophysiology of SARS-CoV-2 infection. The article also focused on vaccine development, herd immunity, and the most promising repurposed therapeutics for the treatment of COVID-19 with their clinical trial updates. Bangladesh Pharmaceutical Journal 24(1): 61-75, 2021

ACE-2-Receptors of the Epidermis, Dermal Vascular Walls and Sebaceous Gland Cells: The Way of COVID-19 Entry into the Body?

2020 ◽  
Author(s):  
Stefan Bittmann
Keyword(s):  
Clinical Trials ◽  
Viral Infection ◽  
Sebaceous Gland ◽  
The Body ◽  
Viral Agent ◽  
Therapy Options ◽  
Vascular Walls ◽  
Fish Market ◽  
The World ◽  
The Usa

Since the outbreak near a fish market in Wuhan, China, in December 2019, researchers have been searching for an effective therapy to control the spreading of the new coronavirus SARS-CoV-2 and inhibit COVID-19 infection. Many countries like Italy, Spain, and the USA were ambushed by this viral agent. To date, more than 2.5 million people were infected with SARS-CoV-2. There is no clear answer, why SARS-CoV-2 infects so many people so fast. To date of April 2020, no effective drug has been found to treat this new severe viral infection. There are many therapy options under review and clinical trials were initiated to get clearer information, what kind of drug can help in this devastating and serious situation. The world has no time.

SARS-CoV-2 Biology Insights, Part IV.Antibody-Dependent Enhancement (ADE) and the tricky “Herd Immunity”: narrative review (Preprint)

2020 ◽  
Author(s):  
Laura Lafon-Hughes
Keyword(s):  
Viral Infection ◽  
Viral Entry ◽  
Neutralizing Antibodies ◽  
Vaccine Development ◽  
Whooping Cough ◽  
Common Knowledge ◽  
Herd Immunity ◽  
Life Quality ◽  
Host Cells ◽  
System P

BACKGROUND It is common knowledge that vaccination has improved our life quality and expectancy since it succeeded in achieving almost eradication of several diseases including chickenpox (varicella), diphtheria, hepatitis A and B, measles, meningococcal, mumps, pneumococcal, polio, rotavirus, rubella, tetanus and whooping cough (pertussis) Vaccination success is based on vaccine induction of neutralizing antibodies that help fight the infection (e.g. by a virus), preventing the disease. Conversely, Antibody-dependent enhancement (ADE) of a viral infection occurs when anti-viral antibodies facilitate viral entry into host cells and enhance viral infection in these cells. ADE has been previously studied in Dengue and HIV viruses and explains why a second infection with Dengue can be lethal. As already reviewed in Part I and Part II, SARS-Cov-2 shares with HIV not only 4 sequences in the Spike protein but also the capacity to attack the immune system. OBJECTIVE As HIV presents ADE, we wondered whether this was also the case regarding SARS-CoV-2. METHODS A literature review was done through Google. RESULTS SARS-CoV-2 presents ADE. As SARS, which does not have the 4 HIV-like inserts, has the same property, ADE would not be driven by the HIV-like spike sequences. CONCLUSIONS ADE can explain the failure of herd immunity-based strategies and will also probably hamper anti-SARS-CoV-2 vaccine development. As reviewed in Part I, there fortunately are promising therapeutic strategies for COVID-19, which should be further developed. In the meantime, complementary countermeasures to protect mainly the youth from this infection are presented to be discussed in Part V Viewpoint.

scholarly journals Cutaneous manifestations in children with the new coronavirus infection COVID-19

2021 ◽  
Vol 25 (1) ◽  
pp. 16-24
Author(s):  
O. B. Tamrazova ◽  
A. S. Stadnikova ◽  
E. V. Rudikova
Keyword(s):  
Literature Review ◽  
Viral Infection ◽  
Causative Agent ◽  
The Novel ◽  
Cutaneous Manifestations ◽  
Skin Manifestations ◽  
The World ◽  
Coronavirus Infection ◽  
Novel Coronavirus

In late 2019, a new viral infection appeared in China, which spread around the world, causing a pandemic. The causative agent of the new coronavirus infection COVID-19 is the SARS-CoV-2 coronavirus. The review presents modern data on the epidemiology, pathogenesis and course of the novel coronavirus infection COVID-19 in children. Chinese, American and European scientists have described a variety of cutaneous manifestations in children with COVID-19. The article provides a literature review of the cutaneous manifestations of COVID-19 coronavirus infection in children. During our own observation of 301 patients with coronavirus infection COVID-19 caused by SARS-CoV-2 at the Bashlyaevs Children Hospital in Moscow from May 17 to November 16, 2020, it was revealed that 39 (13 %) patients had skin manifestations. The article presents a classification of skin manifestations characteristic of COVID-19. A brief description of each group is given.

scholarly journals Nanobiosensors for the Detection of Novel Coronavirus 2019-nCoV and Other Pandemic/Epidemic Respiratory Viruses: A Review

Sensors ◽  
2020 ◽  
Vol 20 (22) ◽  
pp. 6591
Author(s):  
Badriyah Alhalaili ◽  
Ileana Nicoleta Popescu ◽  
Olfa Kamoun ◽  
Feras Alzubi ◽  
Sami Alawadhia ◽  
...  
Keyword(s):  
Public Health ◽  
Vaccine Development ◽  
Respiratory Viruses ◽  
Public Health Emergency ◽  
Detection Methods ◽  
Origin And Evolution ◽  
The World ◽  
Human Coronaviruses ◽  
Novel Coronavirus ◽  
Made In

The coronavirus disease 2019 (COVID-19) pandemic is considered a public health emergency of international concern. The 2019 novel coronavirus (2019-nCoV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused this pandemic has spread rapidly to over 200 countries, and has drastically affected public health and the economies of states at unprecedented levels. In this context, efforts around the world are focusing on solving this problem in several directions of research, by: (i) exploring the origin and evolution of the phylogeny of the SARS-CoV-2 viral genome; (ii) developing nanobiosensors that could be highly effective in detecting the new coronavirus; (iii) finding effective treatments for COVID-19; and (iv) working on vaccine development. In this paper, an overview of the progress made in the development of nanobiosensors for the detection of human coronaviruses (SARS-CoV, SARS-CoV-2, and Middle East respiratory syndrome coronavirus (MERS-CoV) is presented, along with specific techniques for modifying the surface of nanobiosensors. The newest detection methods of the influenza virus responsible for acute respiratory syndrome were compared with conventional methods, highlighting the newest trends in diagnostics, applications, and challenges of SARS-CoV-2 (COVID-19 causative virus) nanobiosensors.

scholarly journals Coronavirus Pandemic: a major public health crisis for the developed and developing world

2021 ◽  
Vol 15 (03) ◽  
pp. 366-369
Author(s):  
Rooh Ullah ◽  
Muhammad Suleman Rana ◽  
Mehmood Qadir ◽  
Muhammad Usman ◽  
Niaz Ahmed
Keyword(s):  
Public Health ◽  
Severe Acute Respiratory Syndrome ◽  
Viral Infection ◽  
The Novel ◽  
Global Public Health ◽  
Health Crisis ◽  
Public Health Crisis ◽  
The World ◽  
Novel Coronavirus ◽  
Day By Day

Pandemic of novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections in China is now become global public health crisis. At present 87.64% of the world is infected by this deadly illness. The risk from this epidemic depends on the nature of the virus, including how well it transmits from person to person, and the complications resulting from this current illness. The novel coronavirus has killed thousands of people in China and other countries as well; its rate of mortality is increasing day by day. There is an urgent need to control the virus by developing vaccine or any other antiviral drugs to save the world from this deadly viral infection.

COVIEdb: A database for potential immune epitopes of coronaviruses

2020 ◽  
Author(s):  
Jingcheng Wu ◽  
Wenfan Chen ◽  
Jingjing Zhou ◽  
Wenyi Zhao ◽  
Shuqing Chen ◽  
...  
Keyword(s):  
Immune System ◽  
Large Scale ◽  
Vaccine Development ◽  
Protein Sequences ◽  
T Cell Epitopes ◽  
Human Immune System ◽  
The World ◽  
Human Immune ◽  
Human Coronaviruses ◽  
Novel Coronavirus

Abstract2019 novel coronavirus (2019-nCoV) has caused large-scale pandemic COVID-19 all over the world. It’s essential to find out which parts of the 2019-nCoV sequence are recognized by human immune system for vaccine development. And for the prevention of the potential outbreak of similar coronaviruses in the future, vaccines against immunogenic epitopes shared by different human coronaviruses are essential. Here we predict all the potential B/T-cell epitopes for SARS-CoV, MERS-CoV, 2019-nCoV and RaTG13-CoV based on the protein sequences. We found YFKYWDQTY in ORF1ab protein, VYDPLQPEL and TVYDPLQPEL in spike (S) protein might be pan-coronavirus targets for vaccine development. All the predicted results are stored in a database COVIEdb (http://biopharm.zju.edu.cn/coviedb/).

scholarly journals COVID-19, Herd Immunity and Nanotechnology- A Review

2021 ◽  
Vol 9 (1) ◽  
pp. 15-21
Author(s):  
Ravi Kumar Sah ◽  
Mukesh Kumar Bhagat ◽  
Upama Niraula
Keyword(s):  
Development Process ◽  
Vaccine Development ◽  
Herd Immunity ◽  
Epidemiological Data ◽  
Review Article ◽  
Economic Sector ◽  
Development Status ◽  
Global Pandemic ◽  
The World ◽  
Epidemiology Data

Covid-19 had been the global pandemic cases across the world since WHO declared it as pandemic diseases. It has been global crisis which had impacted globally on health and economic sector at a time. This review article had covered the detail of COVID-19 in brief detail, its epidemiological data, herd immunity and vaccination program, vaccine development status. Also this article the nanotechnology used in vaccine development process and its future prospective. This article had been concerned over the SAARC Nations epidemiology data related to COVID-19.

scholarly journals The parallels between COVID-19 and the Spanish flu of 1918

2020 ◽  
Vol 7 (11) ◽  
pp. 4687
Author(s):  
Markordor Lyngdoh
Keyword(s):  
Vaccine Development ◽  
Influenza Pandemic ◽  
World Health ◽  
Health Crisis ◽  
The World ◽  
Spanish Flu ◽  
Avian Origin ◽  
1918 Influenza ◽  
Novel Coronavirus ◽  
Health Organization

The 1918 influenza pandemic was the most severe pandemic in recent history. It was caused by an H1N1 virus with genes of avian origin. On the other hand, the ongoing COVID-19 pandemic caused by a novel coronavirus hailed by the world health organization as a “once in a century health crisis” which has led to devastating impacts to health and livelihood the world over. The prevailing situation is reminiscent of the Spanish flu where definitive cure is unavailable and the public health measures like quarantine, social distancing, hand hygiene and isolation are the only alternatives. Both these diseases are transmitted through respiratory droplets, highly contagious and target the respiratory organs. The parallels between these two events cannot be denied. The Spanish flu thrived at a time when the knowledge and availability of antivirals and vaccine development were inadequate. This article strives to highlight a little more on these two separate pandemics and observe their similarities as well as their differences.

scholarly journals COVID-19 and Impact on Pregnant Women

2021 ◽  
pp. 55-61
Author(s):  
Deepali Rajnalwar ◽  
Swaroopa Chakole
Keyword(s):  
Viral Infection ◽  
Pregnant Women ◽  
Clinical Outcomes ◽  
Clinical Symptoms ◽  
Preterm Births ◽  
Vulnerable Groups ◽  
Post Vaccination ◽  
The World ◽  
Novel Coronavirus ◽  
Second Wave

Background: Coronavirus disease 2019 or COVID-19 is the viral infection pandemic that has spread all over the world. Although all people are prone to the infection almost equally, some of them after catching infection may produce more severe clinical symptoms. These are called vulnerable groups and pregnant women are one of them. Summary: Pregnant women were thought to be not affected by the COVID-19 pandemic in the first wave, but recent observations from the second wave which harbors the mutated versions of novel coronavirus, said to be more virulent and lethal, suggests that pregnant women are not only vulnerable to catching the infection but they can show severe clinical outcomes. Also case fatalities, preterm births are also high among COVID-19 infected pregnant women. Conclusion: More vaccination among pregnant women is needed to safeguard them as the severity of the symptoms is lowered post-vaccination. To solidify more results, more comprehensive and frequent studies are needed so that correlation can be established.

scholarly journals The prevention and treatment of Covid-19 and related development during pandemic

2021 ◽  
Vol 16 ◽  
Author(s):  
Chin-Kun Wang ◽  
Yuan-Ti Lee ◽  
Chao-Bin Yeh ◽  
Chi-Ho Chan
Keyword(s):  
Vaccine Development ◽  
Antibody Therapy ◽  
Future Perspective ◽  
Epidemic Spread ◽  
Antibody Treatment ◽  
Related Development ◽  
The World ◽  
Prevention And Treatment ◽  
Novel Coronavirus ◽  
Effective Drugs

When the outbreak of human novel coronavirus was first reported in Wuhan, China at the end of 2019, the epidemic spread rapidly around the world and finally became a pandemic in 2020. In order to seek effective drugs to treat the Covid-19 infected patients for emergent use and for the disease prevention, researchers examined numerous existed antiviral drugs that may have the potential for Covid-19 treatment. At the same time, antibody treatment and vaccines development were ongoing simultaneously. The aim of this review is to introduce antibody therapy, vaccine development and potential antiviral treatments on Covid-19 and to discuss the future perspective on the Covid-19 pandemic.

Sign in / Sign up

Export Citation Format

Share Document